Seaport Therapeutics Reports Q3 GAAP EPS of -$0.49, Exceeding Analyst Expectations
Seaport Therapeutics, Inc. (SPTX) has released its third-quarter financial results, reporting a GAAP Earnings Per Share (EPS) of -$0.49. This figure represents a beat of $0.09 relative to market expectations. The company continues to operate as a development-arbitrage platform focused on balancing efficacy with engineered safety in its therapeutic pipeline. While still reporting net losses typical of clinical-stage biotechnology firms, the earnings beat suggests better-than-anticipated cost management or operational efficiency during the quarter.